The Indian pharmaceuticals space’s growth has been severely hobbled by acute pricing pressure in the US generics market. The next leg of growth will be defined by companies that focus on high margins and complex drugs like biosimilars. Kiran Mazumdar Shaw, CMD of Biocon, was instrumental in putting India on the biosimilar map.

In the first episode of #TheMedicineBox, Shaw breaks down the world of biosimilars and the opportunity it presents. Shaw also weighs in on the vital challenges in the Indian pharma space. Happy Listening!